Podcasts about focus on future medicine and genetics

Host: Mario R. Nacinovich, Jr., MSc Guest: Paul Orchard, MD Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That's why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it's often underdiagnosed and confused with other conditions, and how we can treat it once we've reached an accurate diagnosis.

Host: Mario R. Nacinovich, Jr., MSc Guest: Paul Orchard, MD Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.

Host: Mario R. Nacinovich, Jr., MSc Guest: Paul Orchard, MD Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.

Host: Brian P. McDonough, MD, FAAFP Guest: Cecilia Van Cauwenberghe What was once a sci-fi tale is now a reality, but unlike the aliens and monsters common to this genre, artificial intelligence isn’t something healthcare professionals need to fear. On the contrary, it may just be the key to unlocking new solutions in the pharmaceutical industry, as Dr. Cecilia Van Cauwenberghe explains.

Host: Matt Birnholz, MD Guest: Peng Zhang, PhD Oxygen: It's the third most abundant element in our universe. From healthcare to industrial needs, we know oxygen's uses to be far-reaching, but could there still be more therapeutic potential yet? In an in-depth conversation with Dr. Matt Birnholz, Dr. Pang Zheng presents new evidence of oxygen's potential uses within the healthcare industry.

Data, artificial intelligence, and telehealth protocols are three of the biggest buzzwords in the health care industry right now, but it’s not all just hype. Dean of the Stanford School of Medicine Dr. Lloyd Minor reveals how these three elements are part of his strategic plan for advancing 21st century biomedicine and medical education.

Host: Jennifer Caudle, DO Guest: Jean Bennett, MD, PhD Guest: Albert Maguire, MD Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children's Hospital of Philadelphia.

Host: Jennifer Caudle, DO Guest: Jean Bennett, MD, PhD Guest: Albert Maguire, MD Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.

Host: Jennifer Caudle, DO Guest: Jean Bennett, MD, PhD Guest: Albert Maguire, MD Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.

Host: Jennifer Caudle, DO Guest: Jean Bennett, MD, PhD Guest: Albert Maguire, MD Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.

Host: David Weisman, MD Guest: John Khoury, MD For the first time, the FDA has approved a direct-to-consumer genetic test from 23andme that will inform patients if they are predisposed to diseases such as Parkinson's, Alzheimer's, and Celiac Disease among others. Proponents applaud this decision, saying this will allow for people to know their genetic health risks and be more proactive about their health. Others argue that this information doesn't tell the whole story since predisposition doesn't reflect someone's ultimate risk or likelihood of developing a disease. What are the benefits and liabilities of consumers' access to genetic testing? Host Dr. David Weisman, Director of Clinical Trials at Abington Neurological Associates, sits down with Dr. John Khoury, Associate Director at Abington Memorial Hospital Sleep Disorders Center, to debate the merits and pitfalls of direct-to-consumer genetic testing.

Host: David Weisman, MD Guest: John Khoury, MD For the first time, the FDA has approved a direct-to-consumer genetic test from 23andme that will inform patients if they are predisposed to diseases such as Parkinson’s, Alzheimer's, and Celiac Disease among others. Proponents applaud this decision, saying this will allow for people to know their genetic health risks and be more proactive about their health. Others argue that this information doesn’t tell the whole story since predisposition doesn't reflect someone's ultimate risk or likelihood of developing a disease. What are the benefits and liabilities of consumers' access to genetic testing? Host Dr. David Weisman, Director of Clinical Trials at Abington Neurological Associates, sits down with Dr. John Khoury, Associate Director at Abington Memorial Hospital Sleep Disorders Center, to debate the merits and pitfalls of direct-to-consumer genetic testing.

Host: David Weisman, MD Guest: John Khoury, MD For the first time, the FDA has approved a direct-to-consumer genetic test from 23andme that will inform patients if they are predisposed to diseases such as Parkinson’s, Alzheimer's, and Celiac Disease among others. Proponents applaud this decision, saying this will allow for people to know their genetic health risks and be more proactive about their health. Others argue that this information doesn’t tell the whole story since predisposition doesn't reflect someone's ultimate risk or likelihood of developing a disease. What are the benefits and liabilities of consumers' access to genetic testing? Host Dr. David Weisman, Director of Clinical Trials at Abington Neurological Associates, sits down with Dr. John Khoury, Associate Director at Abington Memorial Hospital Sleep Disorders Center, to debate the merits and pitfalls of direct-to-consumer genetic testing.

Host: Maurice Pickard, MD Guest: Bonnie Rochman With the ever-expanding array of prenatal and postnatal tests, from carrier screening to genome sequencing, parents’ access to this previously unknown information is altering perceptions of disability, redefining the question of what sort of life is worth living, and who draws the line. Is this technology a triumph of modern medicine or a Pandora’s box of possibilities? Host Dr. Maurice Pickard chats with Bonnie Rochman, author of the book The Gene Machine: How Genetic Technologies are Changing the Way We Have Kids - and the Kids We Have, about the new frontier of gene technology and how it is transforming medicine, bioethics, health care, and the factors that shape a family.

Host: Maurice Pickard, MD Guest: Bonnie Rochman With the ever-expanding array of prenatal and postnatal tests, from carrier screening to genome sequencing, parents’ access to this previously unknown information is altering perceptions of disability, redefining the question of what sort of life is worth living, and who draws the line. Is this technology a triumph of modern medicine or a Pandora’s box of possibilities? Host Dr. Maurice Pickard chats with Bonnie Rochman, author of the book The Gene Machine: How Genetic Technologies are Changing the Way We Have Kids - and the Kids We Have, about the new frontier of gene technology and how it is transforming medicine, bioethics, health care, and the factors that shape a family.

Host: Maurice Pickard, MD Guest: Bonnie Rochman With the ever-expanding array of prenatal and postnatal tests, from carrier screening to genome sequencing, parents’ access to this previously unknown information is altering perceptions of disability, redefining the question of what sort of life is worth living, and who draws the line. Is this technology a triumph of modern medicine or a Pandora’s box of possibilities? Host Dr. Maurice Pickard chats with Bonnie Rochman, author of the book The Gene Machine: How Genetic Technologies are Changing the Way We Have Kids - and the Kids We Have, about the new frontier of gene technology and how it is transforming medicine, bioethics, health care, and the factors that shape a family.

Host: Brian P. McDonough, MD, FAAFP Dr. Brian McDonough welcomes Lee Buckler, Director, Chief Executive Officer and President of RepliCel Life Sciences based in Vancouver, BC. Mr. Buckler and his colleagues are tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin.

Host: Shira Johnson, MD Guest: Jean Bennett, MD, PhD There are 39 million people worldwide who are in total blindness and another 246 million with very low vision. The most frequent forms of visual impairment are caused by problems that can be corrected. Dr. Shira Johnson welcomes Dr. Jean Bennett, Professor of Ophthalmology and Cell and Developmental Biology at the University of Pennsylvania and researcher at the Children’s Hospital of Philadelphia. Dr. Bennett discusses her innovative work and research in curing blindness through gene therapy.

Host: Shira Johnson, MD Guest: Jean Bennett, MD, PhD There are 39 million people worldwide who are in total blindness and another 246 million with very low vision. The most frequent forms of visual impairment are caused by problems that can be corrected. Dr. Shira Johnson welcomes Dr. Jean Bennett, Professor of Ophthalmology and Cell and Developmental Biology at the University of Pennsylvania and researcher at the Children’s Hospital of Philadelphia. Dr. Bennett discusses her innovative work and research in curing blindness through gene therapy.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Tim Rush Guest: Asif Ali, MD Most doctors have heard about telemedicine, also called telehealth and e-medicine, but few have actually seen or utilized it in practice. As technologies enabling virtual patient visits and consultations continue to improve and gain more traction by clinicians, how will American healthcare systems change? Joining host Tim Rush to discuss the current and future impacts of telemedicine in health care is Dr. Asif Ali, Clinical Assistant Professor of Cardiology at the University of Texas Health Science Center. Dr. Ali lectures nationwide on the evolving applications of telemedicine in modern practice.

Host: Matt Birnholz, MD Psychiatry gets a bad rep for being one of the more "technophobic" fields in clinical medicine. This negative association stems in part to the difficulty in tracking changes in mood, cognition, and certain behaviors over time. But there is a growing contingency of psychiatric clinicians who are bringing technology into this specialty to help propel standards in mental health care. Dr. Adam Kaplin, Assistant Professor of Psychiatry at Johns Hopkins School of Medicine and Principle Psyciatric Consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers of Excellence, joins Dr. Jennifer Caudle to discuss ways in which technological innovations can enhance psychiatric care and decrease stigma surrounding mental illness.

Host: Matt Birnholz, MD Psychiatry gets a bad rep for being one of the more "technophobic" fields in clinical medicine. This negative association stems in part to the difficulty in tracking changes in mood, cognition, and certain behaviors over time. But there is a growing contingency of psychiatric clinicians who are bringing technology into this specialty to help propel standards in mental health care. Dr. Adam Kaplin, Assistant Professor of Psychiatry at Johns Hopkins School of Medicine and Principle Psyciatric Consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers of Excellence, joins Dr. Jennifer Caudle to discuss ways in which technological innovations can enhance psychiatric care and decrease stigma surrounding mental illness.

Host: Matt Birnholz, MD Psychiatry gets a bad rep for being one of the more "technophobic" fields in clinical medicine. This negative association stems in part to the difficulty in tracking changes in mood, cognition, and certain behaviors over time. But there is a growing contingency of psychiatric clinicians who are bringing technology into this specialty to help propel standards in mental health care. Dr. Adam Kaplin, Assistant Professor of Psychiatry at Johns Hopkins School of Medicine and Principle Psyciatric Consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers of Excellence, joins Dr. Jennifer Caudle to discuss ways in which technological innovations can enhance psychiatric care and decrease stigma surrounding mental illness.

Host: Brian P. McDonough, MD, FAAFP Guest: Sandra Gomberg Technological advances over the past decade have rapidly changed the ways people seek, access, and respond to health care at all levels: patients self-research medical information via health websites, clinicians counsel and treat patients from remote telemedical settings, insurance companies promote patient-controlled health savings accounts, and healthcare organizations monitor internet reviews to predict future cash flow rises and falls. All of these changes point toward a consumer-driven healthcare (CDHC) model, but where will it lead? From the Villanova Healthcare Speaker Event, host Dr. Brian McDonough talks with guest Sandra Gomberg, Chief Operating Officer at Aria Health System. They discuss ways in which medicine has adopted consumer-driven healthcare over time, and what the future holds for patients and clinicians in this system.

Host: Brian P. McDonough, MD, FAAFP Cryotherapy, the science of freezong for medical purposes, uses extreme cold temperatures to cool down the body and has both current and emerging medical applications ranging from brain resuscitation in emergency settings to inflammation reduction in medical spas. Host Dr. Brian McDonough sits down with science and health journalist Renee Ebersole to talk about the rise of cryotherapy, the mechanisms governing its medical utilities, and the benefits vs risks of its applications in various health settings today.

Host: Matt Birnholz, MD Guest: Ronald J. Wapner, MD Innovations in medical genetics are changing the practice of obstetrics and gynecology. With advancing knowledge of underlying genetic predispositions, doctors can provide more precisioned care plans for patients in women's health centers. Dr. Matt Birnholz talks with Dr. Ronald J Wapner, Professor of Obstetrics and Gynecology and Director of Reproductive Genetics at Columbia University, about how the ever-changing field of medical genetics is revolutionizing OB/GYN treatment options and patient care.

Host: Matt Birnholz, MD Guest: Ronald J. Wapner, MD Innovations in medical genetics are changing the practice of obstetrics and gynecology. With advancing knowledge of underlying genetic predispositions, doctors can provide more precisioned care plans for patients in women's health centers. Dr. Matt Birnholz talks with Dr. Ronald J Wapner, Professor of Obstetrics and Gynecology and Director of Reproductive Genetics at Columbia University, about how the ever-changing field of medical genetics is revolutionizing OB/GYN treatment options and patient care.

Host: Matt Birnholz, MD In the ongoing global campaign to prevent, treat, and cure HIV and AIDS, there have been countless therapeutic approaches targeting the HIV virus and everything it interacts with on the path to infection. But after decades of relentless infectivity claiming over 25 million lives, what if we could one day simply edit and delete the HIV virus right out of existence? Joining Dr. Matt Birnholz to discuss a novel research effort to leverage gene editing technology in the fight against HIV is Dr. Kamel Khalili, Professor and Chair of the Department of Neuroscience, Director of the Center for Neuro-virology, and Director of the Comprehensive Neuro-AIDS Center at the Lewis Katz School of Medicine at Temple University.

[Read the Article] Rates of genetic testing for BRCA1 and BRCA2 mutations have increased among younger women diagnosed with breast cancer, according to a new study. The study focused on nearly 900 women diagnosed with breast cancer at age 40 or younger. Researchers looked at rates of genetic testing, barriers to testing, and how the test results affected treatment decisions.In 2006, the rates of BRCA testing were in the seventy percent range and by 2012 that proportion rose to ninety-five percent. While the majority of women reported being tested for BRCA 1 and 2, many were not, and a small minority reported that no one had discussed genetic risk or testing options. The study authors note that the overall goal of genetic testing is to help women make informed treatment decisions. Assessment of a young woman's genetic risk after a breast cancer diagnosis can affect treatment decisions and the results can also have health implications for her relatives. [Watch more videos of The JAMA Report]

[Read the Article] Rates of genetic testing for BRCA1 and BRCA2 mutations have increased among younger women diagnosed with breast cancer, according to a new study. The study focused on nearly 900 women diagnosed with breast cancer at age 40 or younger. Researchers looked at rates of genetic testing, barriers to testing, and how the test results affected treatment decisions.In 2006, the rates of BRCA testing were in the seventy percent range and by 2012 that proportion rose to ninety-five percent. While the majority of women reported being tested for BRCA 1 and 2, many were not, and a small minority reported that no one had discussed genetic risk or testing options. The study authors note that the overall goal of genetic testing is to help women make informed treatment decisions. Assessment of a young woman's genetic risk after a breast cancer diagnosis can affect treatment decisions and the results can also have health implications for her relatives. [Watch more videos of The JAMA Report]

Host: Alicia A. Sutton From the floors of Omnia Education's Women's Health Annual Visit in Washington DC, host Alicia Sutton interviews Dr. Joel Weinthal, Clinical Associate Professor of Pediatrics at Texas Tech University Health Sciences Center and Medical Director of the Stem Cell Transplant Laboratory at Medical City Dallas Hospital. The two discuss Dr. Weinthal's current work in regenerative medicine, the scope of clinical utilization and potential, ethical considerations, and anticipated directions for the field.

Host: Matt Birnholz, MD From mapping AEDs on a phone app to communicating with colleagues on Facebook, technology has become an integral part of daily life. Some would even call their phones an extension of the human nervous system, as evinced by a near-constant awareness of their battery life. Yet despite this high prevalence and demand for social media in regular affairs, medicine has been slow to adopt it. Join Dr. Matt Birnholz and Dr. Nathaniel DeNicola discuss the role of technology and social media in medicine, with particular attention to ACOG's adoption over the past 10 years.

Guest: Dan Roden, MD Host: Bruce Bloom, DDS, JD The greatest side effect of medications is that they often don't do what we expect them to do. Dr. Dan Roden, professor in the departments of medicine and pharmacology at Vanderbilt University School of Medicine, talks with Dr. Bruce Bloom about variability in response to drugs. Genetic components are just one of many reasons patients respond differently. Dr. Roden also discusses his specific work with customizing treatment for patients with arrhythmias based upon the disease mechanism.

Guest: Dan Roden, MD Host: Bruce Bloom, DDS, JD The greatest side effect of medications is that they often don't do what we expect them to do. Dr. Dan Roden, professor in the departments of medicine and pharmacology at Vanderbilt University School of Medicine, talks with Dr. Bruce Bloom about variability in response to drugs. Genetic components are just one of many reasons patients respond differently. Dr. Roden also discusses his specific work with customizing treatment for patients with arrhythmias based upon the disease mechanism.

Host: Mark Nolan Hill, MD Guest: Randi Hagerman, MD We are rapidly learning more about the genetic disorder Fragile X syndrome, and a series of conditions related to Fragile X. We're also seeing great progress in promising therapies under investigation. How will these therapies, along with other treatment strategies, improve the lives of children and families affected by Fragile X and related conditions? Who should supervise care, and should treatment for children be coordinated with care of potentially affected relatives? Dr. Randi Hagerman, professor and endowed chair of Fragile X research, and medical director of the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute at the University of California, Davis School of Medicine, shares her expansive expertise on Fragile X syndrome and associated conditions with host Dr. Mark Nolan Hill. If a child is diagnosed with Fragile X, is genetic screening inevitably warranted for parents and grandparents?

Host: Mark Nolan Hill, MD Guest: Randi Hagerman, MD Diagnosis of the genetic disorder Fragile X syndrome can be devastating for our young patients and their families, knowing that both the patient and their elders can be affected by this condition. Should we expand current screening measures for Fragile X? As clinicians, how do we guide patients and their families through this process of understanding their diagnosis? Dr. Randi Hagerman, professor and endowed chair of Fragile X research, and medical director of the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute at the University of California, Davis School of Medicine, joins host Dr. Mark Nolan Hill to talk about the nuances of this genetic condition.

Host: Mark Nolan Hill, MD Guest: Joseph Muenzer, MD Hunter syndrome is a rare but serious genetic disorder that inhibits the body’s ability to break down specific complex carbohydrates. Initial onset symptoms include inguinal hernias, recurrent otitis, and the common cold, frequently manifesting concurrently as part of a multi-system failure sometime after the first year of life. Because many of these symptoms are common in infants, physicians often do not suspect Hunter syndrome, yet treatment for the disease is much more effective when administered early in its progression. How can we minimize the delay typically associated with diagnosis of Hunter syndrome? Dr. Joseph Muenzer, professor of pediatrics and genetics at the University of North Carolina School of Medicine, and one of the world’s leading authorities in Hunter syndrome research, joins host Dr. Mark Nolan Hill to share his expertise.

Host: Mark Nolan Hill, MD Guest: Joseph Muenzer, MD Previously, patients could only receive palliative care for symptoms associated with Hunter syndrome, a rare but serious genetic disorder that inhibits the body’s ability to break down specific complex carbohydrates. Now, a new enzyme therapy is making it possible to prevent Hunter syndrome manifestation, typically occurring as early as year two, which dramatically improves long-term quality of life. How quickly do patients show improvement with enzyme therapy? What are the most common side effects? Join host Dr. Mark Nolan Hill for an interesting conversation with Dr. Joseph Muenzer, professor of pediatrics and genetics at the University of North Carolina School of Medicine, and one of the world’s leading experts on Hunter syndrome.

Host: Mark Nolan Hill, MD Guest: Joseph Muenzer, MD Hunter syndrome is a rare but serious genetic disorder that inhibits the body’s ability to break down specific complex carbohydrates. What are the prinicipal symptoms that would lead a primary care physician to consider Hunter syndrome? Dr. Joseph Muenzer, professor of pediatrics and genetics at the University of North Carolina School of Medicine, and one of the world’s leading authorities in Hunter syndrome research, joins host Dr. Mark Nolan Hill to share his expertise.

Host: Michael Greenberg, MD Guest: Hugh Rienhoff, MD Dr. Michael Greenberg speaks with Dr. Hugh Rienhoff about www.mydaughtersdna.org, a website he created to help children with rare or difficult-to-diagnose genetic diseases find proper diagnoses and help.

Host: Bruce Bloom, DDS, JD Guest: David Teachey, MD Dr. David Teachey, a practicing pediatric hematologist-oncologist, laboratory and clinical researcher, and instructor in the department of pediatrics, division of oncology, at the Children’s Hospital of Philadelphia, explains to host Bruce Bloom his breakthrough research that may resolve symptoms for children saddled with the rare genetic disorder, Autoimmune Lymphoproliferative Syndrome.

Host: Bruce Bloom, DDS, JD Guest: David Teachey, MD Dr. David Teachey, a practicing pediatric hematologist-oncologist, a world-class laboratory and clinical researcher and an Instructor in the Department of Pediatrics, Division of Oncology, at the Children’s Hospital of Philadelphia discusses his research breakthrough in treating Autoimmune Lymphoproliferative Syndrome.

Host: Bruce Bloom, DDS, JD Guest: David Teachey, MD Dr. David Teachey, a practicing pediatric hematologist-oncologist, a world class laboratory and clinical researcher and an Instructor in the Department of Pediatrics, Division of Oncology, at the Children’s Hospital of Philadelphia discusses his new research repurposing pharmaceutical and botanical medicines for diseases like Lupus and ALPS.